Sankar Navaneethan
Nephrology · Cleveland, OHNPI 1750480562
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $222,620 of the $253,465 with a category attached, or 87.8%. 15 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 28.1% of the total. Among nephrology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $1456.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$71K
- Intercept Pharmaceuticals, Inc.$42K
- Bayer$42K
- Boehringer Ingelheim International GmbH$24K
- Novartis$17K
- Eli Lilly$15K
- plus $43K from 9 others
Across 32 payments — averaging $5358.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$129K
- Vertex$17K
- Travere Therapeutics, Inc.$13K
- Intercept Pharmaceuticals, Inc.$12K
What the payments were for
- Consulting fees$222,62088%
- Speaking & faculty fees$4,5402%
- Travel & lodging$22,3149%
- Food & beverage$3,5161%
- Gifts$4750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 33 | $71,248 |
| Intercept Pharmaceuticals, Inc. | 13 | $42,199 |
| Bayer | 45 | $41,823 |
| Boehringer Ingelheim International GmbH | 13 | $23,597 |
| Novartis | 13 | $16,711 |
| Eli Lilly | 7 | $14,795 |
| Boehringer Ingelheim | 17 | $13,730 |
| GSK | 3 | $8,264 |
| Vertex | 12 | $6,941 |
| AMAG Pharmaceuticals, Inc. | 1 | $5,100 |
| Fresenius USA Marketing, Inc. | 8 | $2,920 |
| Astrazeneca UK Limited | 3 | $2,334 |
| Vifor Pharma, Inc. | 2 | $2,200 |
| AstraZeneca | 2 | $1,556 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$253,465 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- Corey CavanaughCleveland$35K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
- Nishigandha PradhanCleveland$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.